secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2024-09-11T23:59:59+00:00
Accession:  0001140361-24-040837
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals appoints Dr. Mikael Dolsten to board
-----------------------------------------------------------

- Dr. Mikael Dolsten appointed to board effective September 9, 2024.
- Dolsten is Chief Scientific Officer and President, Pfizer R&D since July 2023.
- Granted options to purchase 27,545 shares (vesting over 3 years) and 22,988 shares (vesting in 1 year) at closing market price.
- Entered standard indemnification agreement with the company.
- No arrangements with other persons or family relationships with directors/officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124040837/0001140361-24-040837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124040837/ef20035750_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-040837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer